Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
Scottish Medicines Consortium
Record ID 32018000969
English
Authors' objectives:
To assess clinical and cost effectiveness.
Details
Project Status:
Completed
URL for project:
https://www.scottishmedicines.org.uk/medicines-advice/melatonin-slenyto-resubmission-smc2306/
Year Published:
2021
URL for published report:
https://www.scottishmedicines.org.uk/medicines-advice/melatonin-slenyto-resubmission-smc2306/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Scotland, United Kingdom
MeSH Terms
- Attention Deficit Disorder with Hyperactivity
- Autism Spectrum Disorder
- Melatonin
- Sleep Initiation and Maintenance Disorders
- Child
- Adolescent
- Smith-Magenis Syndrome
Contact
Organisation Name:
Scottish Medicines Consortium (SMC)
Contact Address:
Delta House | 50 West Nile Street
Contact Name:
Susan Downie
Contact Email:
susan.downie3@nhs.scot
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.